These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 26322096)

  • 1. Sulfonylureas and their use in clinical practice.
    Sola D; Rossi L; Schianca GP; Maffioli P; Bigliocca M; Mella R; Corlianò F; Fra GP; Bartoli E; Derosa G
    Arch Med Sci; 2015 Aug; 11(4):840-8. PubMed ID: 26322096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
    Bolen S; Feldman L; Vassy J; Wilson L; Yeh HC; Marinopoulos S; Wiley C; Selvin E; Wilson R; Bass EB; Brancati FL
    Ann Intern Med; 2007 Sep; 147(6):386-99. PubMed ID: 17638715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
    Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
    BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
    Bell DS
    Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
    Yu O; Azoulay L; Yin H; Filion KB; Suissa S
    Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients.
    Kheirandish M; Mahboobi H; Yazdanparast M; Kamal MA
    Curr Drug Metab; 2017; 18(2):157-162. PubMed ID: 28093996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy.
    Derosa G; D'Angelo A; Maffioli P
    Pharmacol Res; 2015 Oct; 100():127-34. PubMed ID: 26211947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.
    Colagiuri S; Matthews D; Leiter LA; Chan SP; Sesti G; Marre M
    Diabetes Res Clin Pract; 2018 Sep; 143():1-14. PubMed ID: 29802958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
    Evans JM; Ogston SA; Emslie-Smith A; Morris AD
    Diabetologia; 2006 May; 49(5):930-6. PubMed ID: 16525843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive drug therapy and hypoglycemia in elderly diabetic patients treated with insulin and/or sulfonylureas. Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA).
    Corsonello A; Pedone C; Corica F; Malara A; Carosella L; Sgadari A; Mauro VN; Ceruso D; Pahor M; Carbonin P
    Eur J Epidemiol; 1999 Nov; 15(10):893-901. PubMed ID: 10669122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
    Del Prato S; Pulizzi N
    Metabolism; 2006 May; 55(5 Suppl 1):S20-7. PubMed ID: 16631807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative safety of newer oral antidiabetic drugs.
    Krentz AJ
    Expert Opin Drug Saf; 2006 Nov; 5(6):827-34. PubMed ID: 17044809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well!
    Abrahamson MJ
    Diabetes Care; 2015 Jan; 38(1):166-9. PubMed ID: 25538313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
    Sicras-Mainar A; Navarro-Artieda R
    Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on!
    Genuth S
    Diabetes Care; 2015 Jan; 38(1):170-5. PubMed ID: 25538314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis.
    Farah D; Leme GM; Eliaschewitz FG; Fonseca MCM
    Diabetes Res Clin Pract; 2019 Mar; 149():47-63. PubMed ID: 30710655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.